...
首页> 外文期刊>Molecules >Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety
【24h】

Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety

机译:新型1,3,4-噻二唑衍生物作为潜在的抗慢性粒细胞性白血病的抗肿瘤药的设计,合成和生物学评估:硝基噻唑部分的显着效果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In an attempt to develop potent antitumor agents, new 1,3,4-thiadiazole derivatives were synthesized and evaluated for their cytotoxic effects on multiple human cancer cell lines, including the K562 chronic myelogenous leukemia cell line that expresses the Bcr-Abl tyrosine kinase. N-(5-Nitrothiazol-2-yl)-2-((5-((4-(trifluoromethyl)phenyl)amino)-1,3,4-thiadiazol-2-yl)thio)acetamide (2) inhibited the Abl protein kinase with an IC50 value of 7.4 μM and showed selective activity against the Bcr-Abl positive K562 cell line. Furthermore, a Bcr-Abl-compound 2 molecular modelling simulation highlighted the anchoring role of the nitrothiazole moiety in bonding and hydrophobic interaction with the key amino acid residues. These results provide promising starting points for further development of novel kinase inhibitors.
机译:为了开发有效的抗肿瘤药,合成了新的1,3,4-噻二唑衍生物,并评估了它们对多种人类癌细胞系(包括表达Bcr-Abl酪氨酸激酶的K562慢性骨髓性白血病细胞系)的细胞毒性作用。 N-(5-硝基噻唑-2-基)-2-((5-((4-(三氟甲基)苯基)氨基)-1,3,4-噻二唑-2-基)硫代)乙酰胺(2)抑制了IC50值为7.4μM的Abl蛋白激酶,对Bcr-Abl阳性K562细胞系表现出选择性活性。此外,Bcr-Abl-化合物2分子建模仿真突出显示了硝噻唑基团在与关键氨基酸残基的键合和疏水相互作用中的锚定作用。这些结果为进一步开发新型激酶抑制剂提供了有希望的起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号